Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT00081224
Other study ID # NCCTG-N0346
Secondary ID NCI-2012-02582CD
Status Terminated
Phase Phase 2
First received April 7, 2004
Last updated December 14, 2016
Start date December 2004
Est. completion date November 2010

Study information

Verified date December 2016
Source Alliance for Clinical Trials in Oncology
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Celecoxib may also make tumor cells more sensitive to chemotherapy and radiation therapy. Giving celecoxib with capecitabine and radiation therapy before surgery may shrink the tumor so that it can be removed.

PURPOSE: This phase II trial is studying how well giving neoadjuvant celecoxib together with capecitabine and pelvic irradiation works in treating patients with stage II or stage III adenocarcinoma (cancer) of the rectum.


Description:

OBJECTIVES:

Primary

- Determine the pathological complete response rate in patients with stage II or III adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in combination with pelvic irradiation.

Secondary

- Determine the safety and tolerability of this regimen in these patients.

- Determine the rectal function of patients treated with this regimen.

- Determine the time to recurrence or progression and survival time of patients treated with this regimen.

- Correlate cellular and molecular markers in pretreatment tumor samples with response in patients treated with this regimen.

OUTLINE: This is a multicenter study.

- Neoadjuvant chemoradiotherapy: Patients receive oral celecoxib twice daily on days 1-7 and oral capecitabine twice daily on days 1-5. Patients undergo pelvic radiotherapy once daily on days 1-5. Courses repeat weekly for 5.5 weeks.

- Surgery: Patients undergo surgery 4-6 weeks after completion of neoadjuvant chemoradiotherapy.

- Adjuvant chemotherapy: Patients with a curative resection receive oral capecitabine twice daily on days 1-14. Treatment repeats every 21 days for up to 4 courses.

Treatment continues in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 4 years.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date November 2010
Est. primary completion date February 2006
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed rectal adenocarcinoma

- Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease

- Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated

- All disease must be encompassable within standard pelvic radiotherapy fields

- Distal border of the tumor must be at or below* the peritoneal reflection, defined as within 12 cm of the anal verge by endoscopy NOTE: *If a portion of the tumor is below the peritoneal reflection at the time of surgery, patients are eligible regardless of the distance of the tumor determined at endoscopy

- Tumor must be determined to be clinically resectable

- Tumor may not be clinically fixed

- Negative margins by routine examination of an unanesthetized patient

- Transmural penetration of tumor through the muscularis propria by CT scan, endorectal ultrasound, or MRI

- No distant metastatic disease

- No evidence of tumor outside the pelvis, including any of the following:

- Metastatic inguinal lymphadenopathy

- Peritoneal seeding

- Liver metastases

PATIENT CHARACTERISTICS:

Age

- 18 and over

Performance status

- ECOG 0-1

Life expectancy

- At least 6 months

Hematopoietic

- Absolute neutrophil count = 1,500/mm^3

- Platelet count = 100,000/mm^3

Hepatic

- Bilirubin = upper limit of normal (ULN)

- AST = 3 times ULN

- Alkaline phosphatase = 4 times ULN if AST < ULN

Renal

- Creatinine clearance = 30 mL/min

- No renal impairment

Cardiovascular

- No congestive heart failure

- No symptomatic coronary artery disease

- No uncontrolled cardiac arrhythmias

- No myocardial infarction

- No history of transient ischemic attacks or stroke

- No other clinically significant cardiac disease

Gastrointestinal

- No bleeding peptic ulcer disease within the past 12 months

- No lack of physical integrity of the upper gastrointestinal tract

- No malabsorption syndrome

- No active inflammatory bowel disease

- Must be able to swallow study drugs

Other

- No dihydropyrimidine dehydrogenase deficiency

- No history of uncontrolled seizures

- No CNS disorders

- No clinically significant psychiatric illness that would preclude study compliance or giving informed consent

- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix

- No known sensitivity to NSAIDs, sulfonamides, or aspirin

- No other serious medical illness that would preclude study treatment

- No other conditions that would preclude study participation

- Must be able to tolerate major surgery that may include abdominal-perineal resection

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during and for 30 days after study treatment

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- See Disease Characteristics

- No prior systemic anticancer chemotherapy

Endocrine therapy

- Not specified

Radiotherapy

- See Disease Characteristics

- No prior radiotherapy to the pelvis

Surgery

- See Disease Characteristics

- More than 3 weeks since prior major surgery and recovered

Other

- At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin

- No other concurrent investigational drugs

- No other concurrent anticancer treatment

- No concurrent NSAIDs

- No concurrent primary prophylactic therapy for hand-foot syndrome

- No concurrent loperamide prophylaxis for diarrhea

- No concurrent sorivudine or brivudine

Study Design

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
capecitabine

celecoxib

Radiation:
radiation therapy

Procedure:
surgery


Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
Alliance for Clinical Trials in Oncology National Cancer Institute (NCI)

Outcome

Type Measure Description Time frame Safety issue
Primary Proportion of successes Up to 5 years No
Secondary Survival time Up to 5 years No
Secondary Time-to event analyses Up to 5 years No
Secondary Time to disease progression/recurrence Up to 5 years No
Secondary Time to recurrence Up to 5 years No
Secondary Time to first progression Up to 5 years No
Secondary Survival Up to 5 years No
Secondary Bowel function as measured by the Patient Bowel Function (Uniscale) Questionnaire, the FACT Diarrhea Subscale and the Mayo Bowel Function Questionnaire Up to 5 years No
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1
Completed NCT01943500 - Collection of Blood Specimens for Circulating Tumor Cell Analysis N/A